Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review
Authors
Keywords
-
Journal
QUALITY OF LIFE RESEARCH
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-11-27
DOI
10.1007/s11136-019-02367-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2
- (2018) Sunil Verma et al. BREAST CANCER RESEARCH AND TREATMENT
- Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy
- (2018) Enriqueta Felip et al. Clinical Lung Cancer
- Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer
- (2018) David J. Vaughn et al. JOURNAL OF CLINICAL ONCOLOGY
- Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The AURA3 Trial
- (2018) Chee Khoon Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial
- (2018) David Cella et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non–Small Cell Lung Cancer: Results from the CheckMate 017 Study
- (2018) Martin Reck et al. Journal of Thoracic Oncology
- Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial
- (2018) Kim N Chi et al. LANCET ONCOLOGY
- Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma
- (2018) Martin J. B. Taphoorn et al. JAMA Oncology
- Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil–cisplatin regimen in oesophageal cancer
- (2017) C. Bascoul-Mollevi et al. EUROPEAN JOURNAL OF CANCER
- Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma
- (2017) Teresa M. Petrella et al. EUROPEAN JOURNAL OF CANCER
- Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Marianne E Pavel et al. LANCET ONCOLOGY
- Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Yung-Jue Bang et al. LANCET ONCOLOGY
- Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
- (2017) Kevin J Harrington et al. LANCET ONCOLOGY
- Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial
- (2017) Julie R Brahmer et al. LANCET ONCOLOGY
- Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study
- (2016) G. V. Long et al. ANNALS OF ONCOLOGY
- Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma
- (2016) S.-E. Al-Batran et al. ANNALS OF ONCOLOGY
- Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial
- (2016) N. Harbeck et al. ANNALS OF ONCOLOGY
- First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial
- (2016) Mark Boye et al. Clinical Lung Cancer
- Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy
- (2016) Frédéric Fiteni et al. EUROPEAN RESPIRATORY JOURNAL
- PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy
- (2016) Sharlene Gill et al. JOURNAL OF CLINICAL ONCOLOGY
- Statistical Challenges in the Analysis of Health-Related Quality of Life in Cancer Clinical Trials
- (2016) Franck Bonnetain et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards
- (2016) Andrew Bottomley et al. LANCET ONCOLOGY
- Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy
- (2016) Maurice Pérol et al. LUNG CANCER
- Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial
- (2016) Zeinab Hamidou et al. PLoS One
- Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial
- (2016) T. Shiroiwa et al. QUALITY OF LIFE RESEARCH
- Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial
- (2016) Aaron Vinik et al. Targeted Oncology
- Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial
- (2015) Javier Cortes et al. BREAST CANCER RESEARCH AND TREATMENT
- Quality of patient-reported outcome reporting across cancer randomized controlled trials according to the CONSORT patient-reported outcome extension: A pooled analysis of 557 trials
- (2015) Fabio Efficace et al. CANCER
- Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer
- (2015) Silvia Novello et al. EUROPEAN JOURNAL OF CANCER
- Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology
- (2015) Frédéric Fiteni et al. Expert Review of Anticancer Therapy
- Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma
- (2015) Martin J.B. Taphoorn et al. JOURNAL OF CLINICAL ONCOLOGY
- Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer
- (2015) Sarayut L Geater et al. Journal of Thoracic Oncology
- Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial
- (2015) Fred Saad et al. LANCET ONCOLOGY
- Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
- (2015) Jean-Pascal H Machiels et al. LANCET ONCOLOGY
- Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial
- (2015) Yohann Loriot et al. LANCET ONCOLOGY
- Patient-reported outcomes as end points and outcome indicators in solid tumours
- (2015) Angeles A. Secord et al. Nature Reviews Clinical Oncology
- Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study
- (2015) Vardit Dror et al. OncoTargets and Therapy
- QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC
- (2015) Yun-Peng Yang et al. Scientific Reports
- Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) Study
- (2014) Rosine Guimbaud et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial
- (2014) Karim Fizazi et al. LANCET ONCOLOGY
- Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial
- (2014) Peter M Ellis et al. LANCET ONCOLOGY
- Quality of Life in the Trastuzumab for Gastric Cancer Trial
- (2014) Taroh Satoh et al. ONCOLOGIST
- Endpoints in cancer clinical trials
- (2014) F. Fiteni et al. Journal of Visceral Surgery
- Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?
- (2013) Amélie Anota et al. QUALITY OF LIFE RESEARCH
- Time to Deterioration in Quality of Life Score as a Modality of Longitudinal Analysis in Patients with Breast Cancer
- (2011) Z. Hamidou et al. ONCOLOGIST
- Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma
- (2010) Franck Bonnetain et al. EUROPEAN JOURNAL OF CANCER
- Survival End Point Reporting in Randomized Cancer Clinical Trials: A Review of Major Journals
- (2008) Simone Mathoulin-Pelissier et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started